Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.

Scientific reports - 23 Jul 2020

Kim Kui-Jin, Kim Ji-Won, Sung Ji Hea, Suh Koung Jin, Lee Ji Yun, Kim Se Hyun, Lee Jeong-Ok, Kim Jin Won, Kim Yu Jung, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok, Kim Hark Kyun, Lee Keun-Wook

Abstract excerpt

PIK3CA mutations are frequently observed in various human cancers including gastric cancer (GC). This study was conducted to investigate the anti-tumor effects of alpelisib, a PI3K p110α-specific inhibitor, using preclinical models of GC. In addition, the combined effects of alpelisib and paclitaxel on GC were evaluated. Among the SNU1, SNU16, SNU484, SNU601, SNU638, SNU668, AGS, and MKN1 GC cells, three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspases
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Mice, Nude

Share to Paclitaxel

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Thiazoles

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32704014
DOI: 10.1038/s41598-020-68998-w
PMCID: PMC7378194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.PMID 32704014Read ↗

Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells WithPIK3CAMutations and Overcoming StrategiesSemantic proximity Read ↗

Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.Semantic proximity Read ↗

Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.Semantic proximity Read ↗

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Semantic proximity Read ↗

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial CancerSemantic proximity Read ↗

Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.Semantic proximity Read ↗

More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.Semantic proximity Read ↗

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Semantic proximity Read ↗

Alpelisib to treat breast cancer.Semantic proximity Read ↗

In vitro anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines.Semantic proximity Read ↗

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.